We report on the accuracy, ease of use and time efficiency of multi-dimensional methods for measuring these valuable conformational restraints.
Our team of conformational experts describe our new paradigm for drug conformational analysis, understanding, control and design.
Using the Conformetrix technology, we show how a series of drug molecules is likely to be mimicking the shape of a native peptide ligand. This work illustrates how scaffold-hopping from peptides to drugs can be readily achieved.
Dr. Harry Finch (C4X NED) discusses the impact that solution conformational preference data is likely to have on drug discovery programmes.
Here we detail how we measure ligand conformetrics using NMR and establish their relationship to the target-bound conformation. These breakthroughs lie at the heart of the productivity of our drug discovery engine.
